Physician profile
Ran Jia
NPI 1598830416
$10,758.05
in general payments reported to CMS, 2019-2025
43 companies · $849 in 2025
The $849 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,652 · 2020: $270 · 2021: $1,427 · 2022: $772 · 2023: $2,461 · 2024: $1,328 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,637.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $863.19 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $830.28 | 2019-2024 | Breztri, Enhertu |
| Gilead Sciences, INC. | $722.44 | 2022-2024 | Epclusa, Veklury, Livdelzi |
| Abbott Laboratories | $599.54 | 2023-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $515.82 | 2019-2024 | Xarelto |
| Allergan, INC. | $491.87 | 2019-2020 | |
| Lilly USA, LLC | $416.16 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $370.30 | 2019 | |
| Novo Nordisk INC | $370.28 | 2019 | |
| Janssen Products, LP | $364.87 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $341.68 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.74 | 2021-2022 | |
| United Therapeutics Corporation | $246.96 | 2021-2024 | Tyvaso |
| Grifols USA, LLC | $246.90 | 2021-2023 | Prolastin-C Liquid |
| Amgen INC. | $242.02 | 2024 | Repatha, Krystexxa |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ran Jia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.